LENZ Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights on March 19, 2025
LENZ Therapeutics (NASDAQ: LENZ), a pre-commercial stage biopharmaceutical company developing aceclidine-based eye drops for presbyopia, has scheduled its fourth quarter and full year 2024 financial results announcement for March 19, 2025, at 4:30 p.m. EST. The company will discuss financial performance and recent corporate developments via a conference call and webcast.
Interested parties can join via phone at (800) 715-9871 (Domestic) or (646) 307-1963 (International) using code 9147301. A webcast replay will be available on the company's website for 30 days after the event.
LENZ Therapeutics (NASDAQ: LENZ), una società biofarmaceutica in fase pre-commerciale che sviluppa colliri a base di aceclidina per la presbiopia, ha programmato l'annuncio dei suoi risultati finanziari del quarto trimestre e dell'intero anno 2024 per il 19 marzo 2025 alle 16:30 EST. L'azienda discuterà le performance finanziarie e i recenti sviluppi aziendali tramite una conferenza telefonica e un webcast.
Le parti interessate possono partecipare telefonicamente al numero (800) 715-9871 (domestico) o (646) 307-1963 (internazionale) utilizzando il codice 9147301. Una registrazione del webcast sarà disponibile sul sito web dell'azienda per 30 giorni dopo l'evento.
LENZ Therapeutics (NASDAQ: LENZ), una empresa biofarmacéutica en etapa precomercial que desarrolla gotas para los ojos a base de aceclidina para la presbicia, ha programado el anuncio de sus resultados financieros del cuarto trimestre y del año completo 2024 para el 19 de marzo de 2025 a las 4:30 p.m. EST. La compañía discutirá el rendimiento financiero y los recientes desarrollos corporativos a través de una llamada de conferencia y un webcast.
Las partes interesadas pueden unirse por teléfono al (800) 715-9871 (nacional) o (646) 307-1963 (internacional) utilizando el código 9147301. Una repetición del webcast estará disponible en el sitio web de la empresa durante 30 días después del evento.
LENZ Therapeutics (NASDAQ: LENZ), 프리커머셜 단계의 생물 제약 회사로, 노안 치료를 위한 아세클리딘 기반의 안약을 개발하고 있으며, 2024년 4분기 및 전체 연도 재무 결과 발표를 2025년 3월 19일 오후 4시 30분 EST로 예정하고 있습니다. 회사는 재무 성과와 최근 기업 개발에 대해 전화 회의 및 웹캐스트를 통해 논의할 것입니다.
관심 있는 분들은 전화로 (800) 715-9871 (국내) 또는 (646) 307-1963 (국제)로 접속하실 수 있으며, 코드 9147301을 사용하시면 됩니다. 웹캐스트 재생은 이벤트 이후 30일 동안 회사 웹사이트에서 제공될 예정입니다.
LENZ Therapeutics (NASDAQ: LENZ), une entreprise biopharmaceutique en phase pré-commerciale développant des gouttes oculaires à base d'aceclidine pour la presbytie, a prévu l'annonce de ses résultats financiers du quatrième trimestre et de l'année entière 2024 pour le 19 mars 2025 à 16h30 EST. L'entreprise discutera de la performance financière et des récents développements d'entreprise lors d'une conférence téléphonique et d'un webcast.
Les parties intéressées peuvent se joindre par téléphone au (800) 715-9871 (national) ou au (646) 307-1963 (international) en utilisant le code 9147301. Une rediffusion du webcast sera disponible sur le site web de l'entreprise pendant 30 jours après l'événement.
LENZ Therapeutics (NASDAQ: LENZ), ein biopharmazeutisches Unternehmen in der präkommerziellen Phase, das auf Aceclidin basierende Augentropfen gegen Presbyopie entwickelt, hat die Bekanntgabe seiner Finanzergebnisse für das vierte Quartal und das gesamte Jahr 2024 für den 19. März 2025 um 16:30 Uhr EST angesetzt. Das Unternehmen wird die finanzielle Leistung und die aktuellen Unternehmensentwicklungen in einer Telefonkonferenz und einem Webcast besprechen.
Interessierte Parteien können telefonisch unter (800) 715-9871 (inland) oder (646) 307-1963 (international) mit dem Code 9147301 teilnehmen. Eine Aufzeichnung des Webcasts wird 30 Tage nach der Veranstaltung auf der Unternehmenswebsite verfügbar sein.
- None.
- None.
SAN DIEGO, March 11, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in people with presbyopia, today announced it will host a webcast on Wednesday, March 19, 2025, at 4:30 p.m. EST to report its fourth quarter and full year 2024 financial results and recent corporate highlights.
To participate in the conference call via telephone, dial (800) 715-9871 (Domestic) or (646) 307-1963 (International) and enter code 9147301. The live webcast can be accessed here and on the LENZ Therapeutics website at www.LENZ-tx.com in the Investors & Media section. A replay of the webcast will be available on the Company’s website for 30 days following the event.
About LENZ Therapeutics
LENZ Therapeutics is a pre-commercial biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in patients with presbyopia. LENZ’s product candidate LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine. LNZ100 was evaluated in the registration-enabling Phase 3 CLARITY study as a potential therapy for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States. The U.S. Food and Drug Administration (FDA) has assigned a Prescription Drug User Fee Act (PDUFA) target action date of August 8, 2025 for LNZ100. LENZ is committed to commercializing an ideal pharmaceutical presbyopia solution that enhances vision for “all eyes, all day”. LENZ is headquartered in San Diego, California. For more information, visit: LENZ-Tx.com.
Contacts:
Dan Chevallard
LENZ Therapeutics
IR@LENZ-Tx.com
FAQ
When will LENZ Therapeutics (LENZ) report Q4 and full year 2024 earnings?
How can investors access LENZ Therapeutics' Q4 2024 earnings call?
What is LENZ Therapeutics' main product in development?
How long will LENZ Therapeutics' Q4 2024 earnings webcast be available for replay?
